Xintela AB publishes Annual Report 2023
Xintela AB (publ) announces that the company’s annual report for 2023 is published on the company’s website www.xintela.se and is attached to this announcement. Link to the annual report: https://www.xintela.se/en/report-archive Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical products in stem cell […]
Xintela AB Year-end Report 2023
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Fourth quarter 2023 for the groupIncome amounted to TSEK 78 (0).Loss before tax totalled TSEK 12,175 (loss: 23,384).Loss per share was SEK 0.03 (loss: 0.09). The year 2023 for the groupIncome amounted to TSEK 78 (0).Loss before and […]
Xintela changes Certified Adviser to Carnegie Investment Bank AB (publ)
Xintela today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ). Xintela has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023. Until then, Erik […]
Xintela AB Interim Report January – September 2023
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Third quarter 2023 for the groupIncome amounted to TSEK 0 (0).Loss before tax totalled TSEK 11,953 (loss: 14,456).Loss per share was SEK 0.02 (loss: 0.11). First nine month 2023 for the groupIncome amounted to TSEK 0 (0).Loss before […]
Xintela AB Interim Report January – June 2023
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Second quarter 2023 for the groupIncome amounted to TSEK 0 (0).Loss before and tax totalled TSEK 18,401 (loss: 18,942).Loss per share* was SEK 0.06 (loss: 0.21). First half year 2023 for the groupIncome amounted to TSEK 0 (0).Loss before […]
Xintela AB Interim Report January – March 2023
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First quarter 2023 for the groupIncome amounted to TSEK 0 (0).Loss before and tax totalled TSEK 15,843 (loss: 16,383).Loss per share* was SEK 0.05 (loss: 0.18). First quarter 2023 for the parent companyIncome amounted to TSEK 0 (0).Loss before […]
Communiqué from the Annual General Meeting of Xintela AB (publ)
Today, Friday 12 May 2023, the Annual General Meeting was held in Xintela AB (publ). The following main decisions were made. The decisions were taken unanimously. Profit allocation and decision on discharge from liabilityThe meeting decided, in accordance with the board’s proposal, that no dividend is to be paid for the financial year 2022 and […]
Xintela AB publishes Annual Report 2022
Xintela AB (publ) announces that the Swedish version of the company’s Annual Report for 2022 is published on the company’s website, www.xintela.se. The English version will be published shortly. Link to the annual report:https://www.xintela.se/en/report-archive Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical […]
Xintela Year-end report 2022
Summary of the year-end report. The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Third quarter 2022 for the group Fourth quarter 2022 for the groupIncome amounted to TSEK 0 (0).Loss before and tax totalled TSEK 23,384 (loss: 18,013).Loss per share* was SEK 0.09 (loss: 0.20). Twelve months 2022 for the groupIncome […]
Xintela and NorthX Biologics sign collaboration framework agreement
Xintela and NorthX Biologics announce they have signed a collaboration framework agreement to facilitate projects of common interest utilizing their complementary resources and competences in developing and manufacturing Advanced Therapy Medicinal Products (ATMPs). Projects to be initiated under the collaboration framework include product and process development, quality management and expansion capacity for manufacturing ATMPs, among […]
